Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
Woodford R, McKeown J, Hoeijmakers L, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank C, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson D, Mcarthur G, Rutkowski P, Neyns B, Sullivan R, Weber J, Carlino M, Ascierto P, Lo S, Long G, Menzies A. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. European Journal Of Cancer 2024, 212: 115055. PMID: 39366209, DOI: 10.1016/j.ejca.2024.115055.Peer-Reviewed Original ResearchConceptsAnti-PD-1 based therapyAnti-PD-1 therapyAnti-PD-1Adjuvant anti-PD-1 therapyBased therapyStage II-IV melanomaMedian time to recurrenceMedian follow-up timeManagement of recurrenceTime to recurrenceTime of recurrenceFollow-up timeRetrospective cohort studyAnti-CTLA4LR recurrenceLocal therapyMelanoma patientsRecurrent diseaseSystemic therapyMelanoma recurrenceMedian ageCohort studyStage IVRecurrenceStage III
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply